Effect of Combination Dexmedetomidine Added to Fentanyl-based Intravenous Patient-controlled Analgesia on Nausea Vomiting in Highly Susceptible Patients Undergoing Lumbar Spinal Surgery: Prospective Double Blinded Randomized Controlled Trial
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01840254 |
Recruitment Status :
Completed
First Posted : April 25, 2013
Last Update Posted : February 7, 2014
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
PONV | Drug: dexmedetomidine Drug: normal saline | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 108 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Outcomes Assessor) |
Primary Purpose: | Prevention |
Study Start Date : | September 2012 |
Actual Primary Completion Date : | September 2013 |
Actual Study Completion Date : | September 2013 |

Arm | Intervention/treatment |
---|---|
Experimental: dexmedetomidine
addition of dexmedetomidine to fentanyl-based intravenous patient controlled analgesia (PCA)
|
Drug: dexmedetomidine |
Placebo Comparator: normal saline
normal saline as a placebo
|
Drug: normal saline |
- total dose and bolus administration of opioid [ Time Frame: an expected average of 48 hrs for requirements of total dose and number of bolus administration of PCA ]After induction of anesthesia, peak velocity of carotid artery blood flow is measured by the pulsed wave Doppler signal obtained from the left common carotid artery. Respirophasic variation of the peak velocity is defined as the difference between the maximum and the minimum values of peak velocity divided by the mean of the two values during one respiratory cycle. Fluid responder is defined as a patient whose stroke volume index is increased ≥15% after volume expansion. The receiver operating characteristic curve analysis to discriminiate fludi responder is performed.
- consequent postoperative nausea and vomiting [ Time Frame: an expected average of 48 hrs for assessing of the 11-points verbal numerical rating scales ]After induction of anesthesia, peak velocity of carotid artery blood flow is measured by the pulsed wave Doppler signal obtained from the left common carotid artery. Respirophasic variation of the peak velocity is defined as the difference between the maximum and the minimum values of peak velocity divided by the mean of the two values during one respiratory cycle. Fluid responder is defined as a patient whose stroke volume index is increased ≥15% after volume expansion. The receiver operating characteristic curve analysis to discriminate fluid responder is performed.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 20 Years to 65 Years (Adult, Older Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
1. female, non-smoking patient who are 20-65 of age scheduled for elective lumbar spine surgery
Exclusion Criteria:
- Bradycardia on EKG (45bpm)
- Atrioventricular conduction disorder
- Uncontrolled hypertension
- angina history
- obesity (BMI ≥ 30 kg/m2)
- Preoperative administration of opioid
- Preoperative administration of antiemetics
- Gastrointestinal disorder history
- Hepatic or renal disease
- Pregnant 11. Foreigner

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01840254
Korea, Republic of | |
Yonsei University College of Medicine | |
Seoul, Korea, Republic of, 120-752 |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Yonsei University |
ClinicalTrials.gov Identifier: | NCT01840254 History of Changes |
Other Study ID Numbers: |
4-2012-0490 |
First Posted: | April 25, 2013 Key Record Dates |
Last Update Posted: | February 7, 2014 |
Last Verified: | February 2014 |
PONV IV PCA dexmedetomidine |
Female non-smoking lumbar spine surgery |
Dexmedetomidine Hypnotics and Sedatives Central Nervous System Depressants Physiological Effects of Drugs Analgesics, Non-Narcotic Analgesics Sensory System Agents |
Peripheral Nervous System Agents Adrenergic alpha-2 Receptor Agonists Adrenergic alpha-Agonists Adrenergic Agonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action |